Silenseed LTD, a clinical stage biopharmaceutical company developing targeted therapies for solid tumors, including pancreatic, prostate and brain tumors, will present at the Biotech Showcase 2018 event on Wednesday, January 10, 2018 at 11:45AM; Track: Franciscan – D (Ballroom Level), at the HILTON SAN FRANCISCO UNION SQUARE, San Francisco, CA, USA. Silenseed’s Chief Executive Officer, Dr. Amotz Shemi, will provide a corporate overview including the recent initiation of a Phase 2 clinical trial in pancreatic cancer, in about 10 U.S. medical centers, and the planned Phase 2a trial assessing efficacy of the company’s drug siG12D-LODER combined with Immune Oncology drugs.